<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605746</url>
  </required_header>
  <id_info>
    <org_study_id>PHX15BN068</org_study_id>
    <nct_id>NCT02605746</nct_id>
  </id_info>
  <brief_title>Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis</brief_title>
  <official_title>A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Hospital and Medical Center, Phoenix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Genomics Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Hospital and Medical Center, Phoenix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is two parallel studies to examine pharmacokinetic (PK), pharmacodynamic (PD), and&#xD;
      pharmacogenetic (PG) endpoints following short-interval therapy (10-14) daily doses without&#xD;
      dose reduction and interruption) with the ALK (anaplastic lymphoma kinase) small-molecule&#xD;
      inhibitor, ceritinib.&#xD;
&#xD;
      The Phase 0 study will investigate:&#xD;
&#xD;
        1. first recurrence GBM patients and&#xD;
&#xD;
        2. patients with CNS metastases from solid tumors such as, but not limited to, NSCLC&#xD;
           (non-small cell lung cancer) and melanoma.&#xD;
&#xD;
      The CNS (central nervous system) metastases Phase 0 is designed to identify PK effects (in&#xD;
      addition to PD, and PG effects on ALK-positive NSCLC metastases), while the GBM Phase 0 is&#xD;
      designed to identify PK, PD, and PG effects in all patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being done to learn about a new drug, Ceritinib (LKD378). The results of the&#xD;
      study may reveal how the drug works for cancer that spreads to the brain (metastases) and for&#xD;
      a type of brain cancer called glioblastoma (GBM). Subjects are persons scheduled to have&#xD;
      surgery to remove the tumor.This study would test how much of the new drug is present in the&#xD;
      tumor, blood, and cerebrospinal fluid (CSF) after taking the drug orally for 10-14 days&#xD;
      before surgery. It is only given to patients who are already scheduled to have surgery to&#xD;
      remove a tumor that has returned. If the drug seems to be working for a subject's tumor,&#xD;
      subject will have the option to continue to receive it as part of a continuation study&#xD;
      looking at the drug effect on preventing the tumor from recurring. Small samples of blood,&#xD;
      tumor tissue, and CSF will be taken. These samples will be sent to and analyzed at the&#xD;
      Barbara Ann Karmanos Cancer Institute (KCI) and to the Translational Genomics Research&#xD;
      Institute (TGen). Subject involvement will be for 10-14 days before surgery and for 30 days&#xD;
      following surgery. Patients with ALK+ solid tumors will be provided the option of continuing&#xD;
      therapy until tumor progression. ALK positivity will be assessed by approved FISH test&#xD;
      (Abbott Molecular Inc) using Vysis break apart probes (defined as 15% or more positive tumor&#xD;
      cells), the Ventana IHC (immunohistochemistry) test, and/or NGS (next generation sequencing).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2016</start_date>
  <completion_date type="Actual">July 12, 2019</completion_date>
  <primary_completion_date type="Actual">November 29, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration</measure>
    <time_frame>at pre-dose on day 10-14(Day 0), 0.5, 1, 2, 4, 6, 8, and 24 hours following single dose of CERITINIB</time_frame>
    <description>Plasma concentration of Ceritinib after 10-14 oral doses of 750 mg. Will be summarized using descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrospinal Concentration</measure>
    <time_frame>collected intraoperatively at 2-4, 4-8, and 22-26 hours following single dose of CERITINIB relative to the final dose on day 10-14</time_frame>
    <description>Cerebrospinal concentration of Ceritinib. Will be summarized using descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intratumoral Concentration</measure>
    <time_frame>collected intraoperatively at 2-4, 4-8, and 22-26 hours following single dose of CERITINIB relative to the final dose on day 10-14</time_frame>
    <description>Intratumoral concentration of Ceritinib. Will be summarized using descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Tissue</measure>
    <time_frame>at baseline(archival) and up to 26 hours post dosing</time_frame>
    <description>Tumor tissue quantification of total and phosphorylated forms of ALK, JAK/STAT5B, and Caspase-3. Will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Cells in M-Phase</measure>
    <time_frame>at baseline and up to 26 hours post dose CERITINIB</time_frame>
    <description>Number of tumor cells in M-phase of cell cycle (PH3). Will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double Strand DNA</measure>
    <time_frame>at baseline and up to 26 hours post dose CERITINIB</time_frame>
    <description>Presence of double-strand DNA damage (γH2AX). Will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Concentration</measure>
    <time_frame>2-4, 4-8, and 22-26 hours post dosing relative to the final Day 10 dose, as compared to the immediate pre-operative MRI scan</time_frame>
    <description>Tissue concentration of CERITINIB compared to contrast enhancing GBM vs. surrounding nonenhancing FLAIR-hyperintense GBM. Will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>2-4 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 2-4 hours prior to craniotomy for tumor resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-8 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 4-8 hours prior to craniotomy for tumor resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22-26 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 22-26 hours prior to craniotomy for tumor resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceritinib 750mg</intervention_name>
    <arm_group_label>2-4 hours</arm_group_label>
    <arm_group_label>22-26 hours</arm_group_label>
    <arm_group_label>4-8 hours</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  One prior resection of GBM or MRI evidence of solid tumor CNS metastasis&#xD;
&#xD;
          -  All GBM and NSLC metastases must be ALK+&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status ≤2&#xD;
&#xD;
          -  Archival tumor tissue block available for research use&#xD;
&#xD;
          -  Ability to understand written informed consent&#xD;
&#xD;
          -  Recovery from toxicities related to prior anticancer therapies to ≤ grade 2 (CTCAE v&#xD;
             4.03). Exception: patients with any grade alopecia&#xD;
&#xD;
          -  The following lab criteria are met:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 10(9th power)/L&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
               -  Platelets ≥ 75 x 10(9th power)/L&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 x upper limit of normal(ULN), except for patients&#xD;
                  with Gilbert's syndrome who may be included if total bilirubin ≤ 3.0 x ULN and&#xD;
                  direct bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Aspartate transaminase (AST) &lt; 3.0 x ULN, except for patients with liver&#xD;
                  metastasis, who are only included if AST &lt; 5 x ULN; alanine transaminase (ALT) &lt;&#xD;
                  3.0 x ULN, except for patients with liver metastasis, who are only included if&#xD;
                  ALT &lt; 5 x ULN&#xD;
&#xD;
               -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Patient has following lab values or has lab values corrected with supplements to be&#xD;
             within normal limits at screening:&#xD;
&#xD;
               -  Potassium ≥ LLN&#xD;
&#xD;
               -  Magnesium ≥ LLN&#xD;
&#xD;
               -  Phosphorus ≥ LLN&#xD;
&#xD;
               -  Total calcium (corrected for serum albumin) ≥ LLN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-morbid condition(s) that prevent safe surgical treatment&#xD;
&#xD;
          -  Active infection or fever &gt; 38.5°C&#xD;
&#xD;
          -  Patients with known hypersensitivity to any excipients of ceritinib&#xD;
&#xD;
          -  Prior therapy with ceritinib&#xD;
&#xD;
          -  Patients with known history of extensive disseminated bilateral interstitial fibrosis&#xD;
             or interstitial lung disease, including a history of pneumonitis, hypersensitivity&#xD;
             pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically&#xD;
             significant radiation pneumonitis (affecting activities of daily living or requiring&#xD;
             therapeutic intervention)&#xD;
&#xD;
          -  Clinically significant uncontrolled heart disease and/or recent cardiac event (within&#xD;
             6 months), such as:&#xD;
&#xD;
               -  history of documented congestive heart failure (New York Heart Association&#xD;
                  functional classification III-IV);&#xD;
&#xD;
               -  uncontrolled hypertension defined by a Systolic Blood Pressure ≥ 160 mm Hg and/or&#xD;
                  Diastolic Blood Pressure ≥ 100 mm Hg, with or without antihypertensive medication&#xD;
&#xD;
               -  initiation or adjustment of antihypertensive medication(s) is allowed prior to&#xD;
                  screening;&#xD;
&#xD;
               -  ventricular arrhythmias; supraventricular and nodal arrhythmias not controlled&#xD;
                  with medication;&#xD;
&#xD;
               -  other cardiac arrhythmia not controlled with medication;&#xD;
&#xD;
               -  corrected QTc &gt; 450 msec using Fridericia correction on the screening ECG&#xD;
&#xD;
          -  Impaired GI function or GI disease that may alter absorption of ceritinib or inability&#xD;
             to swallow up to five ceritinib capsules daily&#xD;
&#xD;
          -  Ongoing GI adverse events &gt; grade 2 (e.g. nausea, vomiting, or diarrhea) at the start&#xD;
             of the study&#xD;
&#xD;
          -  Receiving medications that meet 1 of the following criteria and cannot be discontinued&#xD;
             at least 1 week prior to start of treatment with ceritinib and for the duration of&#xD;
             participation:&#xD;
&#xD;
               -  Medication with a known risk of prolonging the QT interval or inducing Torsades&#xD;
                  de Pointes&#xD;
&#xD;
               -  Strong inhibitors or strong inducers of CYP3A4/5&#xD;
&#xD;
               -  Medications with a low therapeutic index that are primarily metabolized by&#xD;
                  CYP3A4/5, CYP2C8 and/or CYP2C9&#xD;
&#xD;
               -  Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived&#xD;
                  anti-coagulant. Anticoagulants not derived from warfarin are allowed&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
&#xD;
          -  Women of child-bearing potential, unless they are using highly effective methods of&#xD;
             contraception during dosing and for 3 months after the last dose of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nader Sanai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrow Brain and Spine, Phoenix AZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Brain and Spine</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Joseph's Hospital and Medical Center, Phoenix</investigator_affiliation>
    <investigator_full_name>Nader Sanai</investigator_full_name>
    <investigator_title>Research Clinician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceritinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

